Sacituzumab Tirumotecan Reduces Endometrial Cancer Recurrence and Mortality

A significant international study, TroFuse-005/ENGOT-en23/GOG-3095, presented at ESMO 2026 and published in The Lancet, indicates that the new drug sacituzumab tirumotecan (sac-TMT) effectively reduces endometrial cancer recurrence and death. Women treated with sac-TMT after immunotherapy experienced a 41% lower risk of cancer progression and a 32% lower overall risk of death compared to those on standard chemotherapy. These findings suggest a major advancement in treating this cancer.